注射用水の世界市場-2022-2029

市場力学

注射用水市場の成長は、特定の治療を目的としたタンパク質やワクチンなどの医薬品需要の増加、医療施設の急速な発展、ジェネリック製剤の需要、がんや心血管疾患などのさまざまな疾患の有病率の増加によってもたらされます。

医薬品開発への投資拡大が市場成長の原動力となる見込み

がんや心血管疾患など、さまざまな疾患の有病率が上昇していることが、予測期間中に市場を押し上げると予想されます。水は私たちの身体組織の重要な構成要素であり、総重量の約70%を占めています。通常の成人の1日の必要量は、発汗と尿による不可触性水分損失でそれぞれ2～3リットルとなっています。注射用無菌水は、薬物のビヒクルとして非経口的に投与される場合、浸透圧が1リットル当たり112molになるように十分な溶質を導入した後、非経口的に体液を補充するための水源となります。また、最近の市場機会により、サービスプロバイダーは高度な製造設備に著しい投資を行っています。例えば、2021年1月、サーモフィッシャーサイエンティフィックは、ベルギーにおけるノバセップのウイルスベクター製造事業であるHenogen S.A.を8億7,500万米ドルで買収し、ウイルスベクター製造サービスを発表しています。また、富士フイルム株式会社は、生物製剤や先端治療薬のCDMOであるFujifilm Diosynth Biotechnologiesに約9億2800万米ドルを投資しました。

医薬品開発への投資の増加は、研究活動の活発化につながり、注射用水市場に好影響を与えています。

注射用水のコスト高が市場成長の妨げとなる

しかし、注射用水に関連する副作用として、静脈の炎症（注射の技術に起因して発生する可能性がある）、注射部位の痛みなどが挙げられます。また、肝臓や腎臓の病歴が長い患者さんは、注射用水を飲み始める前に医師に相談する必要があります。さらに、授乳中の母親は注射用水を直接摂取することができないため、市場の成長にマイナスの影響を与える可能性があります。

COVID-19の影響分析

COVID-19の登場は、世界の注射用水市場に大きな影響を与えました。近年、非経口投与が主流である複雑ながん治療薬やコビドワクチンなどの生物製剤のパイプラインが増加し、高度な製造支援に対する需要が高まっており、開発・製造受託機関（CDMO）が重要な役割を担っています。このような生物製剤の進歩は、市場の主要なプレーヤーに機会を提供しています。例えば、グリーンライト・バイオサイエンシズと世界のCDMOであるサムスン・バイオロジックスが提携し、サムスン・バイオロジックスがグリーンライトのメッセンジャーRNAワクチン候補COVID-19を大量に製造することになりました。この提携は、グリーンライト社のCOVID-19ワクチン候補の第III相臨床試験および承認取得後の商業販売に向けた製造を推進することを目的としています。一方、世界のサプライチェーンの混乱、製造設備の停止、消耗品・資材の供給不足、生産能力の不足に直面しました。臨床試験の中止や延期も少なくありません。しかし、COVID-19の状況が回復する限り、すべての設備が開かれ、原材料の規制されたサプライチェーンは、製薬会社やバイオ製薬会社に機会を与え、市場の成長を促しています。

世界の注射用水市場レポートでは、約50以上の市場データ表、50以上の図表、200ページ（概算）の範囲でのアクセスを提供することになります。

目次

第1章 市場調査手法とスコープ

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

• アプリケーション別：市場内訳
• エンドユーザー別：市場内訳
• 流通チャネル別：市場内訳
• 地域別：市場内訳

第4章 市場力学

• 市場インパクトファクター
  • 促進要因
    • 心血管疾患の発生率の上昇
    • 研究活動の増加
  • 抑制要因
  • 厳しい規制
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 規制の分析
• プライシング分析
• アンメットニーズ分析

第6章 COVID-19分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、あるいは将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的取り組み
• まとめ

第7章 アプリケーション別

• 臨床薬理学
• 薬物希釈
• 抗菌用途
• その他

第8章 エンドユーザー別

• 製薬会社、バイオテクノロジー企業
• 研究機関
• 病院
• クリニック
• その他

第9章 流通チャネル別

• 病院内薬局
• 小売薬局
• オンライン薬局
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• 治療タイプ別ベンチマーク

第12章 企業プロファイル

• Abbott Laboratories
  • 企業概要
  • 治療タイプのポートフォリオと説明
  • 主なハイライト
  • 財務概要
• AdvaCare Pharma
• B. Braun SE
• FUJIFILM Holdings Corp.
• GlaxoSmithKline Plc
• Merit Healthcare International Inc.,
• Novartis AG
• Pfizer Inc.
• Pharma Cure Laboratories
• Sanofi

第13章 世界の注射用水市場-DataM

Market Overview

Water for Injection Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of x% during the forecast period (2022-2029).

Water for Injection (WFI) is a water quality standard described by pharmacopeial groups globally. It is used for many essential pharmaceutical products and applications, including necessary use for hemofiltration, irrigation, injectable drugs, in the production of some active pharmaceutical ingredients, implantable medical devices, and other various applications.

Market Dynamics

The Water for Injection market growth is driven by the rising demand for medicines such as proteins and vaccines for specific therapy, rapid advancement in healthcare facilities, demand for generic formulations, and increasing prevalence of different disease such cancer and cardiovascular disease.

The rising investment in the development of drugs is expected to drive the market growth

The rising prevalence of different diseases such as cancer and cardiovascular diseases is expected to boost the market over the forecast period. Water is a critical component of our body tissues and accounts for around 70% of total body weight. Average normal adult daily requirements range from two to three liters each for insensible water loss by perspiration and urine production. When it is administered parenterally as a vehicle for drugs, sterile water for injection offers a source of water for parenteral fluid replenishment after sufficient solute is introduced to reach an osmolarity of 112 mol per liter. In addition, recent market opportunities have service providers making remarkable investments in advanced manufacturing facilities. For instance, in January 2021, Thermo Fisher Scientific announced its viral vector manufacturing services through the acquisition of Henogen S.A., Novasep's viral vector manufacturing business in Belgium, for $875 million. Also, Fujifilm Corp. invested around $928 million in Fujifilm Diosynth Biotechnologies, a CDMO of biologics and advanced therapies.

Increasing investment in drug development leads to increasing research activities, which positively impacts on water for injection market.

The high cost of water for injection will hamper the growth of the market

However, the side effects related to water for injections such as inflammation of a vein (that may occur due to the technique of injecting) and pain at the injected site. Also, liver and kidney patients with a long history of this disease have to consult their doctor before starting the water for injection. In addition, a nursing mother cannot take water for injection directly this have a negative impact on the market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global water for injection market. Recently increasing pipeline of biologics, including complex oncology products moslty delivered parenterally, and COVID vaccine production, there is rising demand for technically advanced manufacturing support, in which contract development and manufacturing organizations (CDMOs) are playing a vital role. These advancemnt in biologics provides the opportunity to the key players in the market. For instance, GreenLight Biosciencesand Samsung Biologics, a global CDMO, collaborated, in which Samsung Biologics will manufacture GreenLight's messenger RNA COVID-19 vaccine candidate at large scale. This collaboration aims to drive the production of GreenLight's COVID-19 vaccine candidate for Phase III trials and, it is subject to regulatory approval, commercial sales. On the other hand, global supply chains disruptions, iterupptions in manufacturing facilities, the more companies faced lack of supply of consumables, commodities, and fill-finish capacity. There are many clinical trials were cancelled or postponed. But as far as the situation of COVID-19 is recovering all facilities are opened and regulated supply chains of raw material gives opportunity to pharma and biophrma companies which is drirng the market growth.

Segment Analysis

The pharmaceutical & biotechnology companies segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The pharmaceutical & biotechnology companies segment is expected to boost the market over the period of the forecast. The WFI is essential for drug formulations and other activities in pharma and biotech companies. As per the European medicines agency, 2020 data report, The European Pharmacopoeia provided quality standards for types of water for pharmaceutical use including Purified Water Water for Injections (WFI), and Water for preparation of extracts. The WFI is used in many sterile medicinal products such as biologics, parenteral, haemodiafiltration solutions, peritoneal dialysis solutions, and irrigation solutions. Also, in 2020, Expert Committee on Specifications for Pharmaceutical Preparations (ECSPP), agreed that the monograph mentioned in The International Pharmacopoeia (Water for injections) and the guideline World Health Organization Good manufacturing practices: water for pharmaceutical use is WFI. Moreover, in pharma companies there are so many activities are performed including drug formulation. For instance, in the manufacturing process of injectable products, such as diluting or dissolving drug substances or preparations during the manufacturing of parenteral products, and for the manufacture of water for the preparation of injections. Bulk WFI can be utilized for the end of the cleaning of equipment which is come into contact with injectable products and final rinse to make sure that no subsequent thermal or chemical deproteinization process is applied.

Geographical Analysis

North America region holds the largest market share of the global water for injection market

North America dominates the market for water for injection and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the presence of a large number of key players, an advanced healthcare system, and rising research and development activities. To develop a drug, there is a need to follow regulatory guidelines such as the United States Pharmacopoeia (USP). In addition, due to technology advancements, the key players are designed to meet the needs of the pharmaceutical industry and provide an inexpensive method for producing WFI. For instance, Evoqua's VRx system offers ease of use, carbon filtration, reverse osmosis, UV light, particle filtration, electrodeionization, and ultra-filtration technologies. The VRx system offers users reliable, high-quality WFI.

Furthermore, the new term coming into the market is "Cold WFI''. It has an ambient temperature of both cold and hot WFI are softened and dechlorinated with RO, but the main difference between both types of WFI systems is that cold WFI systems use a second membrane barrier, such as low-pressure ultrafiltration, to ensure microbiological quality in place of energy-intensive distillation processes.

Competitive Landscape

The water for injection market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Abbott Laboratories, AdvaCare Pharma, B. Braun SE, FUJIFILM Holdings Corp., GlaxoSmithKline Plc, Merit Healthcare International Inc., Novartis AG, Pfizer Inc., Pharma Cure Laboratories and Sanofi among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the water for injection market globally.

For instance,

• In July 2021, Nexus Pharmaceuticals launched potassium chloride in water for injection in single-dose IV bags of 10mEq/100mL, 10mEq/50mL, and 20mEq/50mL. This will be available in environmentally friendly cartons of 24 IV bags.
• In 2022, WuXi STA, has announced its first parenteral formulation manufacturing line at the Wuxi city site. In this manufacturing plant fully automatic sterile manufacturing line operates in a full isolation system with an annual capacity of 2 million units.

B. Braun Medical Inc.

Overview:

B. Braun is a German medical and pharmaceutical device company, founded in 1839 and presence in more than 60 countries. It provides healthcare products and it has an out-patient division.

Treatment type Portfolio:

Sterile Water for Injection: It is a colorless, clear, odorless liquid. It is hypotonic, sterile, nonpyrogenic, and contains no bacteriostatic or antimicrobial agents. It is a diluent or solvent suitable for intravascular injection after first having been made nearly isotonic by the addition of a suitable solute. It is available in different volumes such as 1L, 2L, and 3L, 250mL, and 500 ML.

The global water for injection market report would provide access to approximately 50+ market data tables, 50+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet By Application
• 3.2. Market Snippet By End User
• 3.3. Market snippet By Distribution channel
• 3.4. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The rising incidences of cardiovascular diseases
    • 4.1.1.2. The increasing number of research activities
  • 4.1.2. Restraints:
  • 4.1.3. The stringent regulations
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis
• 5.4. Pricing Analysis
• 5.5. Unmet Needs

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 7.1.2. Market Attractiveness Index, By Application Segment
• 7.2. Clinical Pharmacology*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Medication Dilution
• 7.4. Anti-bacterial Application
• 7.5. Others

8. By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Pharmaceutical & Biotechnology Companies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Research Institutes
• 8.4. Hospitals
• 8.5. Clinics
• 8.6. Others

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel

11. Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Treatment type Benchmarking

12. Company Profiles

• 12.1. Abbott Laboratories*
  • 12.1.1. Company Overview
  • 12.1.2. Treatment type Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. AdvaCare Pharma
• 12.3. B. Braun SE
• 12.4. FUJIFILM Holdings Corp.
• 12.5. GlaxoSmithKline Plc
• 12.6. Merit Healthcare International Inc.,
• 12.7. Novartis AG
• 12.8. Pfizer Inc.
• 12.9. Pharma Cure Laboratories
• 12.10. Sanofi

LIST NOT EXHAUSTIVE

13. Global Water for Injection market- DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us